These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26269129)

  • 1. The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer.
    Joung JY; Kim JE; Kim SH; Seo HK; Chung J; Park WS; Hong EK; Lee KH
    BMC Urol; 2015 Aug; 15():82. PubMed ID: 26269129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
    Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
    Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].
    Tabata K; Satoh T; Matsumoto K; Fujita T; Irie A; Iwamura M; Yanagisawa N; Matsuda D; Muramoto M; Kadowaki K; Suyama K; Shoji K; Koh H; Kawakami T; Okayasu I; Egawa S; Baba S
    Nihon Hinyokika Gakkai Zasshi; 2006 Jul; 97(5):712-8. PubMed ID: 16898594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of androgen deprivation therapy for localized prostate cancer: analysis of pT0 evaluated by radical prostatectomy specimen.
    Kadono Y; Yaegashi H; Izumi K; Ueno S; Kitagawa Y; Mizokami A; Asahi H; Kobashi K; Koshida K; Namiki M
    Anticancer Res; 2013 Mar; 33(3):1147-51. PubMed ID: 23482794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Finding of no tumor (pT0) in patients undergoing radical retropubic prostatectomy for clinically localized prostate cancer.
    Prayer-Galetti T; Gardiman M; Sacco E; Fracalanza S; Betto G; Pinto F
    Anal Quant Cytol Histol; 2007 Apr; 29(2):79-86. PubMed ID: 17484271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
    Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
    Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
    Miyake H; Sakai I; Inoue TA; Hara I; Fujisawa M
    Urol Int; 2006; 77(2):122-6. PubMed ID: 16888415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
    McKay RR; Montgomery B; Xie W; Zhang Z; Bubley GJ; Lin DW; Preston MA; Trinh QD; Chang P; Wagner AA; Mostaghel EA; Kantoff PW; Nelson PS; Kibel AS; Taplin ME
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):364-372. PubMed ID: 29263420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer.
    Noguchi M; Noda S; Nakashima O; Kojiro M
    Oncol Rep; 2002; 9(5):1075-80. PubMed ID: 12168076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neoadjuvant hormonal therapy versus surgery alone for radical prostatectomy in high-risk prostate cancer patients].
    Kobayashi M; Saito Y; Komaru A; Fukasawa S; Suyama T; Akakura K; Ichikawa T; Ueda T
    Hinyokika Kiyo; 2013 Jul; 59(7):411-8. PubMed ID: 23945319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients.
    Mauermann J; Fradet V; Lacombe L; Dujardin T; Tiguert R; Tetu B; Fradet Y
    Eur Urol; 2013 Jul; 64(1):19-25. PubMed ID: 22901983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy.
    Stewart SB; Cheville JC; Sebo TJ; Frank I; Boorjian SA; Thompson RH; Gettman MT; Tollefson MK; Umbriet EC; Psutka SP; Bergstralh EJ; Rangel L; Karnes RJ
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):332-7. PubMed ID: 25156060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy.
    Thalgott M; Rack B; Horn T; Heck MM; Eiber M; Kübler H; Retz M; Gschwend JE; Andergassen U; Nawroth R
    Anticancer Res; 2015 Oct; 35(10):5679-85. PubMed ID: 26408743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
    Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
    Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.
    Miyata Y; Nakamura Y; Yasuda T; Matsuo T; Ohba K; Furusato B; Fukuoka J; Sakai H
    Prostate; 2017 Oct; 77(14):1408-1415. PubMed ID: 28845514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follow-up of nondetectable prostate carcinoma (pT0) after prolonged PSA-monitored neoadjuvant hormonal therapy followed by radical prostatectomy.
    Köllermann J; Caprano J; Budde A; Weidenfeld H; Weidenfeld M; Hopfenmüller W; Helpap B
    Urology; 2003 Sep; 62(3):476-80. PubMed ID: 12946750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.
    Cortés-González JR; Castellanos E; Sandberg K; Eriksson MH; Wiklund P; Carlsson S; Cohn-Cedermark G; Harmenberg U; Gustafsson O; Levitt SH; Lennernäs B; Brandberg Y; Márquez M; Kälkner KM; Nilsson S
    Int J Oncol; 2013 Jan; 42(1):109-17. PubMed ID: 23151842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
    Hara I; Miyake H; Hara S; Gotoh A; Eto H; Arakawa S; Kamidono S
    Hinyokika Kiyo; 2001 Jul; 47(7):453-8. PubMed ID: 11523127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.
    Tosco L; Laenen A; Briganti A; Gontero P; Karnes RJ; Albersen M; Bastian PJ; Chlosta P; Claessens F; Chun FK; Everaerts W; Gratzke C; Graefen M; Kneitz B; Marchioro G; Salas RS; Tombal B; Van den Broeck T; Moris L; Battaglia A; van der Poel H; Walz J; Bossi A; De Meerleer G; Haustermans K; Van Poppel H; Spahn M; Joniau S
    Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):407-412. PubMed ID: 28485390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence.
    Miyata Y; Sakai H; Kanda S; Igawa T; Hayashi T; Kanetake H
    Urology; 2004 Jun; 63(6):1184-90. PubMed ID: 15183987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.